Matches in Nanopublications for { ?s ?p "DDI between Amprenavir and Zonisamide - Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if amprenavir is initiated, discontinued or dose changed. [drugbank_resource:DB00701_DB00909]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00701_DB00909 label "DDI between Amprenavir and Zonisamide - Amprenavir, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if amprenavir is initiated, discontinued or dose changed. [drugbank_resource:DB00701_DB00909]" assertion.